Conclusions

NGS can identify clinically relevant mutations in a significant proportion of advanced cancer patients in LMIC settings. However, real-world application is hindered by limited access to targeted therapies and clinical trials. Strategies to improve access and infrastructure are essential to realise the full potential of precision oncology in these regions.